How Big Is the GBS Market | Trends & Forecast Analysis 2031

Q: How big is the GBS market?

The GBS market was estimated at USD 609.7 million in 2024 and is projected to reach USD 939.5 million by 2031

Q: What factors are driving the GBS market?

Drivers include increased diagnosis, IVIG therapy adoption, and higher incidence linked to viral infections.

Q: Who are the top companies in the GBS market?

Key players include Grifols, CSL Behring, Takeda, Octapharma, and Baxter.

Q: What are some recent trends in the market?

Trends include AI in diagnostics, monoclonal therapies, biosimilars, and plasma exchange innovations.

Q: How does 6W market outlook report help businesses in making decisions?

6W monitors the market across 60+ countries Globally, publishing an annual market outlook report that analyses trends, key drivers, Size, Volume, Revenue, opportunities, and market segments. This report offers comprehensive insights, helping businesses understand market dynamics and make informed decisions.

Q: Do you also provide customisation in the market study?

Yes, we provide customisation as per your requirements. To learn more, feel free to contact us on sales@6wresearch.com

Code: MTA6117

Publication Date: Jul 2025

What is the size of the GBS Market?

According to 6Wresearch internal database and industry insights, the Guillain-Barré Syndrome (GBS) Market was estimated at USD 609.7 million in 2024 and is projected to reach USD 939.5 million by 2031, growing at a CAGR of 6.4% during the forecast period 2025–2031.

Due to improved diagnostic awareness, increased incidence linked with viral infections, and advances in immunotherapy treatments, the Guillain Barre Syndrome market is predicted for the strong growth in the coming years.

Key Growth Drivers of the GBS Market

Rising incidence of autoimmune and post-infectious neurological conditions
Increased use of intravenous immunoglobulin (IVIG) and plasma exchange
Improved healthcare infrastructure and early diagnosis
Growing research on neuroinflammation and immune-mediated diseases
Supportive regulatory pathways for rare disease therapies

GBS Market Trends

GBS market is expanding its landscape in the recent years with notable trends such as rising demand for advanced plasma-derived therapies and biosimilars. The neuro-monitoring and early intervention are shaping care standards. Further, the hospitals are adopting AI-powered diagnostic tools and integrating telemedicine for faster referral and treatment planning. Collectively, all these trends are reshaping the dynamics of the market.

Emerging Developments in the GBS Market

GBS market is being advanced with developments in research into monoclonal antibody therapies which are expanding. Further, the clinical trials are focusing on relapse prevention and long-term recovery outcomes. Aside from these, AI-based biomarkers and predictive analytics are improving patient monitoring and rehabilitation strategies in both acute and chronic phases. Together, all these developments are enhancing the presence of the market worldwide.